Difference between revisions of "Renal cell carcinoma with fibromyomatous stroma"

From Libre Pathology
Jump to navigation Jump to search
 
(3 intermediate revisions by the same user not shown)
Line 2: Line 2:


''Renal cell carcinoma with leiomyomatous stroma'' redirects here.
''Renal cell carcinoma with leiomyomatous stroma'' redirects here.
==General==
*Rare tumour: 12 in >500 renal cell carcinomas with clear cells.<ref name=pmid36592877/>


==Microscopic==
==Microscopic==
Line 27: Line 30:
!CD10
!CD10
!CK34betaE12 (K903)
!CK34betaE12 (K903)
!GPNMB
![[GPNMB]]
|-
|-
|Clear cell renal cell carcinoma  
|Clear cell renal cell carcinoma  
Line 47: Line 50:
| -ve
| -ve
|-
|-
|TSC/mTOR-mutated renal cell carcinoma
|Renal cell carcinoma with fibromyomatous stroma
| +ve
| +ve
| +ve
| +ve
Line 55: Line 58:
|}
|}
==Molecular==
==Molecular==
*[[Renal neoplasms with TSC/mTOR pathway mutations|TSC/mTOR pathway mutation]].
*[[Renal neoplasms with TSC/mTOR pathway mutations|TSC/mTOR pathway mutation]].<ref name=pmid36592877/>


==See also==
==See also==

Latest revision as of 13:30, 26 March 2024

Renal cell carcinoma with fibromyomatous stroma, abbreviated RCC FMS, is an evolving subtype of renal cell carcinoma.[1]

Renal cell carcinoma with leiomyomatous stroma redirects here.

General

  • Rare tumour: 12 in >500 renal cell carcinomas with clear cells.[2]

Microscopic

Features:[2]

  • Fibromyomatous stroma (smooth muscle stroma) - key feature.
  • Varied architecture: nested, solid, tubular, tubulopapillary.
  • WHO/ISUP grade 3 or 4.
  • Nuclei not polarized in the cell.

DDx:

IHC

Features:[2]

  • CD10 +ve.
  • CK7 +ve (most).
  • CA9 +ve.

Comparison between some renal tumours with clear cells

Tumour CK7 CD10 CK34betaE12 (K903) GPNMB
Clear cell renal cell carcinoma -ve (may be focal) +ve -ve usu. -ve
Clear cell papillary renal cell tumour +ve (diffuse) -ve +ve -ve[3]
ELOC-mutated renal cell carcinoma +ve +ve -ve -ve
Renal cell carcinoma with fibromyomatous stroma +ve +ve -ve +ve

Molecular

See also

References

  1. Trpkov K, Williamson SR, Gill AJ, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, Argani P, Chen YB, Cheng L, Epstein JI, Cheville JC, Comperat E, da Cunha IW, Gordetsky JB, Gupta S, He H, Hirsch MS, Humphrey PA, Kapur P, Kojima F, Lopez JI, Maclean F, Magi-Galluzzi C, McKenney JK, Mehra R, Menon S, Netto GJ, Przybycin CG, Rao P, Rao Q, Reuter VE, Saleeb RM, Shah RB, Smith SC, Tickoo S, Tretiakova MS, True L, Verkarre V, Wobker SE, Zhou M, Hes O (June 2021). "Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia". Mod Pathol 34 (6): 1167–1184. doi:10.1038/s41379-021-00737-6. PMID 33526874.
  2. 2.0 2.1 2.2 2.3 Tjota MY, Sharma A, Wanjari P, Fitzpatrick C, Segal J, Antic T (April 2023). "TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases". Hum Pathol 134: 124–133. doi:10.1016/j.humpath.2022.12.015. PMID 36592877.
  3. Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, Matoso A (November 2023). "Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others". Am J Surg Pathol 47 (11): 1267–1273. doi:10.1097/PAS.0000000000002117. PMID 37661807.